HUP0003761A2 - Substituted alkanohydroxamic acids and pharmaceutical compositions containing them - Google Patents
Substituted alkanohydroxamic acids and pharmaceutical compositions containing themInfo
- Publication number
- HUP0003761A2 HUP0003761A2 HU0003761A HUP0003761A HUP0003761A2 HU P0003761 A2 HUP0003761 A2 HU P0003761A2 HU 0003761 A HU0003761 A HU 0003761A HU P0003761 A HUP0003761 A HU P0003761A HU P0003761 A2 HUP0003761 A2 HU P0003761A2
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- alkanohydroxamic acids
- substituted alkanohydroxamic
- substituted
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
- C07D209/66—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with oxygen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90397597A | 1997-07-31 | 1997-07-31 | |
PCT/US1998/015868 WO1999006041A1 (en) | 1997-07-31 | 1998-07-30 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0003761A2 true HUP0003761A2 (en) | 2001-03-28 |
HUP0003761A3 HUP0003761A3 (en) | 2001-04-28 |
Family
ID=25418328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0003761A HUP0003761A3 (en) | 1997-07-31 | 1998-07-30 | Substituted alkanohydroxamic acids and pharmaceutical compositions containing them |
Country Status (20)
Country | Link |
---|---|
US (3) | US6214857B1 (hu) |
EP (1) | EP1035848B1 (hu) |
JP (1) | JP2001511448A (hu) |
KR (1) | KR100716475B1 (hu) |
CN (1) | CN1265590A (hu) |
AT (1) | ATE238052T1 (hu) |
AU (1) | AU737008B2 (hu) |
BR (1) | BR9815895A (hu) |
CA (1) | CA2295295A1 (hu) |
CZ (1) | CZ299873B6 (hu) |
DE (1) | DE69813876T2 (hu) |
ES (1) | ES2196592T3 (hu) |
FI (1) | FI119841B (hu) |
HU (1) | HUP0003761A3 (hu) |
NO (1) | NO315043B1 (hu) |
NZ (1) | NZ502379A (hu) |
PT (1) | PT1035848E (hu) |
RU (1) | RU2199530C2 (hu) |
TR (1) | TR200000221T2 (hu) |
WO (1) | WO1999006041A1 (hu) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
KR100539030B1 (ko) * | 1996-08-12 | 2005-12-27 | 셀진 코포레이션 | 면역치료제 및 이를 이용하여 사이토카인 농도를 감소시키는 방법 |
ES2196592T3 (es) * | 1997-07-31 | 2003-12-16 | Celgene Corp | Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa. |
CA2319173A1 (en) * | 1998-02-11 | 1999-08-19 | Jingwu Duan | Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
DE122010000047I1 (de) | 2001-06-26 | 2011-05-05 | Amgen Fremont Inc | Antikörper gegen opgl |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
MXPA04009996A (es) | 2002-04-12 | 2005-07-01 | Celgene Corp | Metodos para la identificacion de moduladores de la angiogenesis, compuestos descubiertos por los mismos, y metodos de tratamiento usando los compuestos. |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
AU2003234624B8 (en) * | 2002-05-17 | 2009-03-12 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
US7842691B2 (en) * | 2002-10-15 | 2010-11-30 | Celgene Corporation | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
WO2004041181A2 (en) * | 2002-10-31 | 2004-05-21 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
US20060165649A1 (en) * | 2002-11-06 | 2006-07-27 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
CA2505131A1 (en) | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
BR0316256A (pt) * | 2002-11-18 | 2005-10-04 | Celgene Corp | Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto |
JP2006510617A (ja) * | 2002-11-18 | 2006-03-30 | セルジーン・コーポレーション | (+)−3−(3,4−ジメトキシ−フェニル)−3−(1−オキソ−1,3−ジヒドロ−イソインドール−2−イル)−プロピオンアミドの使用方法およびそれを含む組成物 |
ZA200505308B (en) | 2002-12-30 | 2006-10-25 | Celgene Corp | Fluoroalkoxy-substituted 1, 3-Dihydro-Isoindolyl compounds and their pharmaceutical uses |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
JP2006519875A (ja) * | 2003-03-06 | 2006-08-31 | セルジーン・コーポレーション | 中枢神経系障害を治療するための選択的サイトカイン阻害剤 |
JP4713465B2 (ja) * | 2003-03-12 | 2011-06-29 | セルジーン コーポレイション | 7−アミド−イソインドリル化合物およびその薬学的使用 |
CN100427465C (zh) * | 2003-03-12 | 2008-10-22 | 细胞基因公司 | N-烷基-异羟肟酸-异吲哚基化合物及其药物用途 |
WO2004080422A2 (en) * | 2003-03-12 | 2004-09-23 | Celgene Corporation | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
DE10340739A1 (de) * | 2003-09-04 | 2005-04-07 | Satia Gmbh | Verfahren zur enzymatischen Herstellung von Mono- und Diacylglycerid-haltigen Emulgatoren |
CA2543132A1 (en) * | 2003-10-23 | 2005-05-19 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
US20080213213A1 (en) * | 2004-04-14 | 2008-09-04 | Zeldis Jerome B | Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione |
WO2005102317A1 (en) * | 2004-04-23 | 2005-11-03 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
WO2005112917A1 (en) * | 2004-05-05 | 2005-12-01 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
EP1750697A4 (en) * | 2004-05-05 | 2009-08-26 | Celgene Corp | METHODS AND COMPOSITIONS USING CYTOKINE INHIBITION DRUGS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
US7405237B2 (en) | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
JP2008518924A (ja) * | 2004-10-28 | 2008-06-05 | セルジーン・コーポレーション | 中枢神経系損傷の治療及び管理のためのpde4モジュレータを使用する方法及び組成物 |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
EP2049120A4 (en) | 2006-07-31 | 2011-09-07 | Janssen Pharmaceutica Nv | UROTENSIN II RECEPTOR ANTAGONISTS |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
PA8782701A1 (es) * | 2007-06-07 | 2009-01-23 | Janssen Pharmaceutica Nv | Antagonistas del receptor de urotensina ii |
SI2203439T1 (sl) | 2007-09-14 | 2011-05-31 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni |
CA2732762A1 (en) * | 2008-08-02 | 2010-02-11 | William A. Kinney | Urotensin ii receptor antagonists |
BRPI0918055A2 (pt) | 2008-09-02 | 2015-12-01 | Addex Pharmaceuticals Sa | derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato. |
CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
JP2012517441A (ja) | 2009-02-10 | 2012-08-02 | セルジーン コーポレイション | 結核の治療、予防及び管理のためのpde4モジュレーターの使用法及び含有組成物 |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
BRPI1010831A2 (pt) | 2009-05-12 | 2016-04-05 | Addex Pharmaceuticals Sa | derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2 |
ME01573B (me) | 2009-05-12 | 2014-09-20 | Addex Pharma Sa | DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA |
MX341050B (es) | 2010-04-07 | 2016-08-05 | Celgene Corp * | Metodos para tratar infeccion viral respiratoria. |
AU2011268450B2 (en) | 2010-06-15 | 2015-07-16 | Amgen (Europe) GmbH | Biomarkers for the treatment of psoriasis |
WO2012062751A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
CN102976974B (zh) * | 2012-12-29 | 2015-01-21 | 吉首大学 | 苯基苄基丙酰-n-甲基氧肟酸类尿素酶抑制剂及其合成和用途 |
CN102993153B (zh) * | 2012-12-29 | 2015-05-13 | 吉首大学 | 异黄酮-n-甲基氧肟酸类尿素酶抑制剂及其合成和用途 |
CN102993152B (zh) * | 2012-12-29 | 2015-04-01 | 吉首大学 | 尿素酶抑制剂异黄酮氧肟酸化合物及其合成和用途 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
LT3096790T (lt) | 2014-01-21 | 2019-10-10 | Janssen Pharmaceutica, N.V. | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
SI3431106T1 (sl) | 2014-01-21 | 2021-03-31 | Janssen Pharmaceutica Nv | Kombinacije, ki vsebujejo pozitivne alosterične modulatorje metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba |
US20170087129A1 (en) | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
MX2016014384A (es) | 2014-06-23 | 2017-01-20 | Celgene Corp | Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado. |
WO2017030892A1 (en) | 2015-08-14 | 2017-02-23 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
KR102445637B1 (ko) * | 2017-11-28 | 2022-09-22 | 솔브레인 주식회사 | 레벨링제 및 이를 포함하는 전기도금 조성물 |
CN110386893A (zh) * | 2018-04-17 | 2019-10-29 | 天津合美医药科技有限公司 | 异吲哚衍生物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4077998A (en) * | 1975-10-28 | 1978-03-07 | Morton-Norwich Products, Inc. | Phthaloyl amino acid hydroxamic acids |
US4173652A (en) | 1976-12-18 | 1979-11-06 | Akzona Incorporated | Pharmaceutical hydroxamic acid compositions and uses thereof |
US4820828A (en) | 1987-03-04 | 1989-04-11 | Ortho Pharmaceutical Corporation | Cinnamohydroxamic acids |
US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
NZ305940A (en) | 1995-07-26 | 1999-05-28 | Pfizer | N-(aroyl)glycine hydroxamic acid derivatives and related compounds that inhibit the production of tnf and are useful in treating asthma |
ES2196592T3 (es) * | 1997-07-31 | 2003-12-16 | Celgene Corp | Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa. |
-
1998
- 1998-07-30 ES ES98938151T patent/ES2196592T3/es not_active Expired - Lifetime
- 1998-07-30 HU HU0003761A patent/HUP0003761A3/hu unknown
- 1998-07-30 RU RU2000102639/04A patent/RU2199530C2/ru not_active IP Right Cessation
- 1998-07-30 CN CN98807775A patent/CN1265590A/zh active Pending
- 1998-07-30 TR TR2000/00221T patent/TR200000221T2/xx unknown
- 1998-07-30 BR BR9815895-3A patent/BR9815895A/pt not_active Application Discontinuation
- 1998-07-30 AT AT98938151T patent/ATE238052T1/de not_active IP Right Cessation
- 1998-07-30 WO PCT/US1998/015868 patent/WO1999006041A1/en active IP Right Grant
- 1998-07-30 CZ CZ20000256A patent/CZ299873B6/cs not_active IP Right Cessation
- 1998-07-30 DE DE69813876T patent/DE69813876T2/de not_active Expired - Fee Related
- 1998-07-30 JP JP2000504855A patent/JP2001511448A/ja active Pending
- 1998-07-30 NZ NZ502379A patent/NZ502379A/xx unknown
- 1998-07-30 US US09/126,157 patent/US6214857B1/en not_active Expired - Fee Related
- 1998-07-30 CA CA002295295A patent/CA2295295A1/en not_active Abandoned
- 1998-07-30 AU AU86741/98A patent/AU737008B2/en not_active Ceased
- 1998-07-30 KR KR1020007001011A patent/KR100716475B1/ko not_active IP Right Cessation
- 1998-07-30 EP EP98938151A patent/EP1035848B1/en not_active Expired - Lifetime
- 1998-07-30 PT PT98938151T patent/PT1035848E/pt unknown
-
1999
- 1999-12-28 NO NO19996529A patent/NO315043B1/no not_active IP Right Cessation
-
2000
- 2000-01-12 FI FI20000061A patent/FI119841B/fi active IP Right Grant
-
2001
- 2001-02-09 US US09/780,725 patent/US6656964B2/en not_active Expired - Fee Related
-
2003
- 2003-06-16 US US10/462,319 patent/US7091356B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2001511448A (ja) | 2001-08-14 |
US6656964B2 (en) | 2003-12-02 |
EP1035848A4 (en) | 2001-05-23 |
NZ502379A (en) | 2002-10-25 |
ATE238052T1 (de) | 2003-05-15 |
TR200000221T2 (tr) | 2000-09-21 |
RU2199530C2 (ru) | 2003-02-27 |
BR9815895A (pt) | 2001-01-16 |
PT1035848E (pt) | 2003-09-30 |
DE69813876T2 (de) | 2004-01-29 |
NO996529D0 (no) | 1999-12-28 |
AU8674198A (en) | 1999-02-22 |
CZ299873B6 (cs) | 2008-12-17 |
AU737008B2 (en) | 2001-08-09 |
DE69813876D1 (de) | 2003-05-28 |
FI119841B (fi) | 2009-04-15 |
EP1035848A1 (en) | 2000-09-20 |
KR20010022429A (ko) | 2001-03-15 |
KR100716475B1 (ko) | 2007-05-10 |
FI20000061A (fi) | 2000-03-02 |
US20010049371A1 (en) | 2001-12-06 |
NO315043B1 (no) | 2003-06-30 |
US7091356B2 (en) | 2006-08-15 |
CA2295295A1 (en) | 1999-02-11 |
EP1035848B1 (en) | 2003-04-23 |
US6214857B1 (en) | 2001-04-10 |
US20040006096A1 (en) | 2004-01-08 |
NO996529L (no) | 2000-03-28 |
CZ2000256A3 (cs) | 2000-06-14 |
WO1999006041A1 (en) | 1999-02-11 |
ES2196592T3 (es) | 2003-12-16 |
CN1265590A (zh) | 2000-09-06 |
HUP0003761A3 (en) | 2001-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0003761A3 (en) | Substituted alkanohydroxamic acids and pharmaceutical compositions containing them | |
HUP0100178A3 (en) | Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof | |
HUP0001309A3 (en) | 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them | |
IL119078A (en) | Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them | |
IL114622A0 (en) | Heteroaryl-oxazolidinones and pharmaceutical compositions containing them | |
HUP9701554D0 (en) | Pharmaceutical composition containing plazma proteins | |
IL135177A0 (en) | Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same | |
HUP0004398A3 (en) | Alpha-aryl-n-alkylnitrones and pharmaceutical compositions containing the same | |
GB9706089D0 (en) | Pharmaceutical composition | |
HUP9901452A3 (en) | Bicyclic-aromatic compounds and pharmaceutical compositions containing them | |
HUP0100085A3 (en) | Biphenylamidine derivatives and pharmaceutical compositions containing them | |
HUP0101701A3 (en) | Substituted betha-alanines and pharmaceutical compositions comprising them | |
HUP0002331A3 (en) | 20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof | |
IL136612A (en) | Phenylaminoalkyl-carboxylic acid derivatives and pharmaceutical compositions containing the same | |
IL133928A0 (en) | Pharmaceutical composition containing peptichemio | |
GB9717444D0 (en) | Pharmaceutical composition | |
CY2298B1 (en) | Pharmaceutical composition containing 4-oxo-butynic acids | |
HUP0002455A3 (en) | Gastric-retained pharmaceutical composition | |
AP9901657A0 (en) | Pharmaceutical compositions | |
GB9717428D0 (en) | Pharmaceutical composition | |
IL136045A0 (en) | Pyridylpyrrole derivatives and pharmaceutical compositions containing the same | |
GB9717770D0 (en) | Pharmaceutical composition | |
GB2321190B (en) | Pharmaceutical composition | |
IL122872A0 (en) | Quinoxaline-and quinoxalinylalkane-phosphonic acids their preparation and pharmaceutical compositions containing them | |
GB9726781D0 (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |